Filing Overview
This Form 8-K reports matters submitted to stockholders at Eliem Therapeutics, Inc.’s 2023 Annual Meeting, held virtually on May 18, 2023. The filing identifies the registrant as Eliem Therapeutics, Inc., not Climb Bio, Inc. The common stock traded under ticker ELYM on Nasdaq.
Voting Results
| Proposal | Result | Votes |
|---|---|---|
| Election of Simon Tate as Class II director | Approved | 21,144,596 for; 555,897 withheld; 891,450 broker non-votes |
| Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2023 | Approved | 22,574,271 for; 3,897 against; 13,775 abstentions; no broker non-votes |
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes and Outlook
The filing does not provide financial guidance, operational outlook, management commentary, new contingencies, or unusual financial items. The principal governance changes were the election of Simon Tate to serve through the 2026 Annual Meeting and stockholder ratification of PwC as the 2023 independent auditor.
Items for Investor Verification
- Verify the issuer identity: the supplied metadata names Climb Bio, Inc., while the filing names Eliem Therapeutics, Inc.
- Verify the filing and signature dates. The report date is May 18, 2023, but the signature block states May 19, 2022, which appears inconsistent.
- Confirm Simon Tate’s board classification and term through the 2026 Annual Meeting.
- Review the definitive proxy statement filed April 6, 2023 for proposal details and voting procedures.
- Consult the company’s periodic financial filings for financial performance, liquidity, debt, and outlook information not included in this 8-K.